Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

Obesity pipeline

Trial arms side by side.

One row is one arm. A blank cell is n/r. A comparator gap appears only when the source states that gap.

ClassNone selected
MechanismNone selected

No arms selected. Choose a drug, an arm, or a preset.

Each arm uses its closest stored timepoint inside the window.

Cross-trial values

value

Source: Cited trial source for each arm. The timepoint in the table is the one this chart used.

No selected arm has this endpoint inside the time window.

Show as table
ArmTrialPhasePopulationnComparatorTimepointEstimandAssessorValue

Not shown

Every selected arm is drawn.

299 of 2118 arms with a reported figure. Choose arms to narrow the chart.

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

X axis: threshold category. Y axis: participants reaching threshold, %.

83.531.188.738.38729.272.517.79612921234.590.986.4130.5581.5598.496994.3710.6596.052094.3792.6529.4191.4324.449.860.21545.961.460.725.9818282.831.516.523.749.649.935.613.850.521.951.823.9861.4738.8253.567.4974.9180.5282.5266.12318659274.1288.7475.8461.9857.4776.1618.411.92615154058.197.773.392.297.610039.4947.9816.4450.4817.1166.3942.4944.5318.8744.966.717.36662.139.248.643.346.215.59.15.6
≥5%
87.766.734.190.570.49.261.88.169.588.6863.4388.034.8192.11485.9283.8214.7170723.935.53.3318.0335.0933.911.165.565.668.810.633.123.414.44.326.16.322.776.5530.4519.7518.9436.5755.9557.7664.6133.9843.9753.4935.7924.0615.2839.4320.1724.637.4427.277.0241.4920.2118.495.660.0555.632.345.580
≥10%
71.74556.197.947.82.553.44.851.782.5741.4273.942.0682.891.3363.3872.062.9448.571.97.317.709.8422.8112.55.637.945.954.718.118.92
≥15%
5531.176.499.623.3037.43.233.980.9622.9854.931.0303.2812.28
≥20%
  • Semaglutide 2.4 mg
  • Semaglutide Semaglutide placebo
  • Semaglutide 7.2 mg
  • Semaglutide Placebo
  • Semaglutide 15 mg
  • Semaglutide 2.4 mg
  • Semaglutide Semaglutide
  • Semaglutide Placebo (semaglutide)
  • Semaglutide 2.4 mg
  • Semaglutide 2.4 mg
  • Semaglutide Semaglutide
  • Semaglutide Placebo
  • Semaglutide 2.4 mg
  • Semaglutide Placebo
  • Semaglutide Semaglutide, on treatment
  • Semaglutide Placebo, on treatment
  • Tirzepatide Placebo
  • Tirzepatide 15 mg
  • Tirzepatide 15 mg
  • Tirzepatide Placebo
  • Tirzepatide 10 mg
  • Tirzepatide Tirzepatide MTD
  • Tirzepatide Placebo
  • Tirzepatide Tirzepatide
  • Tirzepatide Placebo
  • Tirzepatide 15 mg
  • Tirzepatide Placebo
  • Tirzepatide 10 mg
  • Tirzepatide 15 mg
  • Tirzepatide Placebo
  • Tirzepatide 10 mg
  • Orforglipron Placebo
  • Orforglipron 6 mg
  • Orforglipron 12 mg
  • Orforglipron Placebo QD
  • Orforglipron 6 mg
  • Orforglipron 12 mg
  • Survodutide 0.6 mg
  • Survodutide Placebo group
  • Survodutide 2.4 mg
  • Survodutide 3.6 mg
  • Survodutide 4.8 mg
  • Exenatide Group A
  • Exenatide Group B
  • Liraglutide Liraglutide Placebo, Pre-diabetes
  • Liraglutide 3.0 mg
  • Liraglutide 3.0 mg
  • Liraglutide 1.8 mg
  • Liraglutide Placebo
  • Liraglutide 3.0 mg
  • Liraglutide Placebo
  • Liraglutide 3.0 mg
  • Liraglutide Placebo
  • Liraglutide 3.0 mg
  • Liraglutide Placebo, in trial
  • Liraglutide 0.05 mg
  • Liraglutide 0.1 mg
  • Liraglutide 0.2 mg
  • Liraglutide 0.3 mg
  • Liraglutide 0.4 mg
  • Liraglutide 3.0 mg
  • Liraglutide Placebo + Metformin
  • Liraglutide 100 mcg
  • Liraglutide 200 mcg
  • Liraglutide 300 mcg
  • Liraglutide 2.4 mg
  • Liraglutide 4.5 mg
  • Liraglutide 1.2 mg
  • Liraglutide 0.6 mg
  • Liraglutide 0.3 mg
  • Liraglutide 3.0 mg
  • Lixisenatide Lixisenatide
  • Lixisenatide Sitagliptin
  • CT-868 CT-868 Placebo
  • CT-868 1.8 mg
  • CT-868 4.1 mg
  • CT-868 6.6 mg
  • Bimagrumab 30 mg
  • Bimagrumab 30 mg
  • Bimagrumab 30 mg
  • Bimagrumab 1.0 mg
  • Bimagrumab 2.4 mg
  • Bimagrumab 1.0 mg
  • Bimagrumab 2.4 mg
  • Naltrexone And Bupropion NB16
  • Naltrexone And Bupropion NB32
  • Naltrexone And Bupropion Placebo
  • Naltrexone And Bupropion NB32
  • Naltrexone And Bupropion Placebo
  • Naltrexone And Bupropion NB32
  • Naltrexone And Bupropion Placebo
  • Naltrexone And Bupropion NB32
  • Naltrexone And Bupropion Placebo
  • Phentermine And Topiramate VI-0521 Low
  • Phentermine And Topiramate VI-0521 Top
  • Phentermine And Topiramate Placebo
  • Phentermine And Topiramate VI-0521 Top
  • Phentermine And Topiramate VI-0521 Mid
  • Phentermine And Topiramate TPM 46
  • Phentermine And Topiramate TPM 92
  • Phentermine And Topiramate PHEN 7.5
  • Phentermine And Topiramate PHEN 15
  • Phentermine And Topiramate Placebo
  • Setmelanotide Placebo
  • Setmelanotide Setmelanotide
  • Setmelanotide Pivotal Cohort
  • Setmelanotide Setmelanotide
  • Setmelanotide Setmelanotide
  • Setmelanotide Setmelanotide
  • Setmelanotide Placebo
Show as table
Arm≥5%≥10%≥15%≥20%
Semaglutide 2.4 mg83.5%n/rn/rn/r
Semaglutide Semaglutide placebo31.1%n/rn/rn/r
Semaglutide 7.2 mg88.7%n/rn/rn/r
Semaglutide 2.4 mgn/rn/rn/rn/r
Semaglutide Placebo38.3%n/rn/rn/r
Semaglutide Semaglutiden/rn/rn/rn/r
Semaglutide Placebo (semaglutide)n/rn/rn/rn/r
Semaglutide 1.0 mgn/rn/rn/rn/r
Semaglutide 2.4 mgn/rn/rn/rn/r
Semaglutide Semaglutide placebo I/IIn/rn/rn/rn/r
Semaglutide Semaglutiden/rn/rn/rn/r
Semaglutide Placebon/rn/rn/rn/r
Semaglutide 2.4 mgn/rn/rn/rn/r
Semaglutide Placebo, in trialn/rn/rn/rn/r
Semaglutide 15 mgn/r87.7%71.7%55%
Semaglutide 2.4 mgn/r66.7%45%31.1%
Semaglutide 2.4 mgn/rn/rn/rn/r
Semaglutide Semaglutide placebo OWn/rn/rn/rn/r
Semaglutide Semaglutiden/rn/rn/rn/r
Semaglutide Semaglutide placebon/rn/rn/rn/r
Semaglutide 2.4 mgn/rn/rn/rn/r
Semaglutide Placebo, in trialn/rn/rn/rn/r
Semaglutide Insuline glargine U100 (reduced) + semaglutiden/rn/rn/rn/r
Semaglutide Insuline glargine U100 (titrated)n/rn/rn/rn/r
Semaglutide Semaglutiden/r34.1%56.1%76.4%
Semaglutide Placebo (semaglutide)n/r90.5%97.9%99.6%
Semaglutide 7.2 mgn/rn/rn/rn/r
Semaglutide 2.4 mgn/rn/rn/rn/r
Semaglutide Placebon/rn/rn/rn/r
Semaglutide 2.4 mg87%70.4%47.8%23.3%
Semaglutide 2.4 mg29.2%9.2%2.5%0%
Semaglutide 2.4 mgn/rn/rn/rn/r
Semaglutide 2.4 mgn/rn/rn/rn/r
Semaglutide 1.7 mgn/rn/rn/rn/r
Semaglutide 1.7 mgn/rn/rn/rn/r
Semaglutide Semaglutiden/rn/rn/rn/r
Semaglutide Placebo (semaglutide)n/rn/rn/rn/r
Semaglutide Semaglutiden/rn/rn/rn/r
Semaglutide Placebon/rn/rn/rn/r
Semaglutide 2.4 mgn/rn/rn/rn/r
Semaglutide Placebo, in trialn/rn/rn/rn/r
Semaglutide Placebon/rn/rn/rn/r
Semaglutide 2.4 mgn/rn/rn/rn/r
Semaglutide Semaglutiden/rn/rn/rn/r
Semaglutide Placebo (semaglutide)n/rn/rn/rn/r
Semaglutide Semaglutide72.5%61.8%53.4%37.4%
Semaglutide Placebo17.7%8.1%4.8%3.2%
Semaglutide 2.4 mg96%n/rn/rn/r
Semaglutide Placebo12%n/rn/rn/r
Semaglutide Semaglutide, on treatment92%n/rn/rn/r
Semaglutide Placebo, on treatment12%n/rn/rn/r
Tirzepatide Placebo34.5%n/rn/rn/r
Tirzepatide 5 mgn/rn/rn/rn/r
Tirzepatide 10 mgn/rn/rn/rn/r
Tirzepatide 15 mg90.9%n/rn/rn/r
Tirzepatide 15 mg86.41%69.58%51.78%33.98%
Tirzepatide Placebo30.55%8.68%2.57%0.96%
Tirzepatide 10 mg81.55%63.43%41.42%22.98%
Tirzepatide Tirzepatide (lead-in)n/rn/rn/rn/r
Tirzepatide Tirzepatide MTD98.49%n/rn/rn/r
Tirzepatide Placebo69%n/rn/rn/r
Tirzepatide Tirzepatiden/rn/rn/rn/r
Tirzepatide Placebon/rn/rn/rn/r
Tirzepatide Tirzepatide94.37%88.03%73.94%54.93%
Tirzepatide Placebo10.65%4.81%2.06%1.03%
Tirzepatide Tirzepatide MTD_GPI1n/rn/rn/rn/r
Tirzepatide Placebo_GPI1n/rn/rn/rn/r
Tirzepatide Tirzepatide MTD_GPI2n/rn/rn/rn/r
Tirzepatide Placebo_GPI2n/rn/rn/rn/r
Tirzepatide 15 mg96.05%92.11%82.89%n/r
Tirzepatide Placebo20%4%1.33%n/r
Tirzepatide 10 mg94.37%85.92%63.38%n/r
Tirzepatide 15 mg92.65%83.82%72.06%n/r
Tirzepatide Placebo29.41%14.71%2.94%n/r
Tirzepatide 10 mg91.43%70%48.57%n/r
Orforglipron Placebo24.4%7%1.9%n/r
Orforglipron 6 mg49.8%23.9%7.3%n/r
Orforglipron 12 mg60.2%35.5%17.7%n/r
Orforglipron Placebo QD15%3.33%0%0%
Orforglipron 6 mg45.9%18.03%9.84%3.28%
Orforglipron 12 mg61.4%35.09%22.81%12.28%
Cagrilintide/semaglutide cagrilintide 2.4 mg and semaglutide 2.4 mgn/rn/rn/rn/r
Cagrilintide/semaglutide Placebo s.c.n/rn/rn/rn/r
Retatrutide 4 mgn/rn/rn/rn/r
Retatrutide 9 mgn/rn/rn/rn/r
Retatrutide 12 mgn/rn/rn/rn/r
Retatrutide Placebon/rn/rn/rn/r
Survodutide 3.6 mgn/rn/rn/rn/r
Survodutide 6.0 mgn/rn/rn/rn/r
Survodutide Placebon/rn/rn/rn/r
Survodutide 0.6 mg60.7%33.9%12.5%n/r
Survodutide Placebo group25.9%11.1%5.6%n/r
Survodutide 2.4 mg81%65.5%37.9%n/r
Survodutide 3.6 mg82%65.6%45.9%n/r
Survodutide 4.8 mg82.8%68.8%54.7%n/r
VK2735 2.5 mgn/rn/rn/rn/r
VK2735 15 mgn/rn/rn/rn/r
VK2735 Placebo 13 weeksn/rn/rn/rn/r
Eloralintide Placebon/rn/rn/rn/r
Eloralintide 1 mgn/rn/rn/rn/r
Eloralintide 3 mgn/rn/rn/rn/r
Eloralintide 6 mgn/rn/rn/rn/r
Eloralintide 9 mgn/rn/rn/rn/r
Berobenatide Placebon/rn/rn/rn/r
Dulaglutide Dulaglutide Armn/rn/rn/rn/r
Dulaglutide Placebo Armn/rn/rn/rn/r
Exenatide Group An/rn/rn/rn/r
Exenatide Group Bn/rn/rn/rn/r
Exenatide Exenatiden/rn/rn/rn/r
Exenatide Placebon/rn/rn/rn/r
Exenatide Exenatide once weekly (EQW )n/rn/rn/rn/r
Exenatide Dapagliflozin (DAPA)n/rn/rn/rn/r
Exenatide EQW plus DAPAn/rn/rn/rn/r
Exenatide Dapagliflozin plus Glucophage (MET ER)n/rn/rn/rn/r
Exenatide Phentermine /Topiramate (PHEN/ TPM) ERn/rn/rn/rn/r
Exenatide Exenatide once weekly extended-releasen/rn/rn/rn/r
Exenatide Matching placebon/rn/rn/rn/r
Exenatide Group A31.5%n/rn/rn/r
Exenatide Group B16.5%n/rn/rn/r
Liraglutide 3.0mgn/rn/rn/rn/r
Liraglutide 3.0mgn/rn/rn/rn/r
Liraglutide Liraglutide Placebo, no Pre-diabetesn/rn/rn/rn/r
Liraglutide Liraglutide Placebo, Pre-diabetes23.7%10.6%n/rn/r
Liraglutide 3.0 mg49.6%33.1%n/rn/r
Liraglutide 3.0 mg49.9%23.4%n/rn/r
Liraglutide 1.8 mg35.6%14.4%n/rn/r
Liraglutide Placebo13.8%4.3%n/rn/r
Liraglutide 3.0 mg50.5%26.1%n/rn/r
Liraglutide Placebo21.9%6.3%n/rn/r
Liraglutide 3.0 mg51.8%22.77%n/rn/r
Liraglutide Placebo23.98%6.55%n/rn/r
Liraglutide 3.0 mgn/rn/rn/rn/r
Liraglutide Placebon/rn/rn/rn/r
Liraglutide Semaglutiden/rn/rn/rn/r
Liraglutide Liraglutiden/rn/rn/rn/r
Liraglutide Placebo (liraglutide)n/rn/rn/rn/r
Liraglutide Liraglutiden/rn/rn/rn/r
Liraglutide Placebon/rn/rn/rn/r
Liraglutide 3.0 mg61.47%30.45%18.11%n/r
Liraglutide Placebo, in trial38.82%19.75%8.92%n/r
Liraglutide Liraglutiden/rn/rn/rn/r
Liraglutide Placebon/rn/rn/rn/r
Liraglutide Metformin XR plus liraglutiden/rn/rn/rn/r
Liraglutide Metformin XR plus placebon/rn/rn/rn/r
Liraglutide Liraglutide Pen Injector (Saxenda)n/rn/rn/rn/r
Liraglutide Placebo liraglutide pen injectorn/rn/rn/rn/r
Liraglutide Liraglutiden/rn/rn/rn/r
Liraglutide Placebon/rn/rn/rn/r
Liraglutide 0.05 mg53.5%18.94%n/rn/r
Liraglutide 0.1 mg67.49%36.57%n/rn/r
Liraglutide 0.2 mg74.91%55.95%n/rn/r
Liraglutide 0.3 mg80.52%57.76%n/rn/r
Liraglutide 0.4 mg82.52%64.61%n/rn/r
Liraglutide 3.0 mg66.12%33.98%n/rn/r
Liraglutide Placebo + Metformin3%n/rn/rn/r
Liraglutide Liraglutide + Metforminn/rn/rn/rn/r
Liraglutide 100 mcg18%n/rn/rn/r
Liraglutide 200 mcg65%n/rn/rn/r
Liraglutide 300 mcg92%n/rn/rn/r
Liraglutide 2.4 mg74.12%43.97%n/rn/r
Liraglutide 4.5 mg88.74%53.49%n/rn/r
Liraglutide 1.2 mg75.84%35.79%n/rn/r
Liraglutide 0.6 mg61.98%24.06%n/rn/r
Liraglutide 0.3 mg57.47%15.28%n/rn/r
Liraglutide 3.0 mgn/rn/rn/rn/r
Liraglutide 3.0 mg76.16%39.43%n/rn/r
Liraglutide 3.0 mgn/rn/rn/rn/r
Liraglutide 3.0 mgn/rn/rn/rn/r
Liraglutide 3.0 mgn/rn/rn/rn/r
Liraglutide 3.0 mgn/rn/rn/rn/r
Liraglutide Orlistatn/rn/rn/rn/r
Lixisenatide Lixisenatide18.4%n/rn/rn/r
Lixisenatide Sitagliptin11.9%n/rn/rn/r
Mazdutide 3/6 Milligrams (mg) Mazdutiden/rn/rn/rn/r
Mazdutide 10 mgn/rn/rn/rn/r
Mazdutide 16 mgn/rn/rn/rn/r
Mazdutide Placebon/rn/rn/rn/r
Mazdutide 6 mgn/rn/rn/rn/r
Oral Semaglutide Oral semaglutiden/rn/rn/rn/r
Oral Semaglutide Oral semaglutide placebon/rn/rn/rn/r
Oral Semaglutide 25 mgn/rn/rn/rn/r
Oral Semaglutide Oral semaglutide placebon/rn/rn/rn/r
Oral Semaglutide 50 mgn/rn/rn/rn/r
Oral Semaglutide oral semaglutide placebo once dailyn/rn/rn/rn/r
TERN-601 250 mgn/rn/rn/rn/r
TERN-601 500 mgn/rn/rn/rn/r
TERN-601 750 mgn/rn/rn/rn/r
TERN-601 Matching Placebon/rn/rn/rn/r
CT-868 CT-868 Placebo2%n/rn/rn/r
CT-868 1.8 mg6%n/rn/rn/r
CT-868 4.1 mg15%n/rn/rn/r
CT-868 6.6 mg15%n/rn/rn/r
HM15211 HM15211n/rn/rn/rn/r
HM15211 Placebon/rn/rn/rn/r
Pramlintide Placebo-P + Placebo-Mn/rn/rn/rn/r
Pramlintide 360 mcgn/rn/rn/rn/r
Pramlintide 5.0 mgn/rn/rn/rn/r
Pramlintide 2.5 mgn/rn/rn/rn/r
Pramlintide 5.0 mgn/rn/rn/rn/r
Pramlintide 1.25 mgn/rn/rn/rn/r
Pramlintide 2.5 mgn/rn/rn/rn/r
Pramlintide 5.0 mgn/rn/rn/rn/r
Pramlintide 1n/rn/rn/rn/r
Pramlintide 2n/rn/rn/rn/r
Pramlintide 3n/rn/rn/rn/r
Pramlintide Placebon/rn/rn/rn/r
Pramlintide Pramlintide + Metreleptinn/rn/rn/rn/r
Pramlintide Pramlintide Acetate and Placebon/rn/rn/rn/r
Pramlintide Lead-In Periodn/rn/rn/rn/r
Bimagrumab 30 mg40%n/rn/rn/r
Bimagrumab 30 mg58.1%n/rn/rn/r
Bimagrumab 30 mg97.7%n/rn/rn/r
Bimagrumab 1.0 mg73.3%n/rn/rn/r
Bimagrumab 2.4 mg92.2%n/rn/rn/r
Bimagrumab 1.0 mg97.6%n/rn/rn/r
Bimagrumab 2.4 mg100%n/rn/rn/r
Naltrexone And Bupropion NB1639.49%20.17%n/rn/r
Naltrexone And Bupropion NB3247.98%24.63%n/rn/r
Naltrexone And Bupropion Placebo16.44%7.44%n/rn/r
Naltrexone And Bupropion NB3250.48%27.27%n/rn/r
Naltrexone And Bupropion Placebo17.11%7.02%n/rn/r
Naltrexone And Bupropion NB3266.39%41.49%n/rn/r
Naltrexone And Bupropion Placebo42.49%20.21%n/rn/r
Naltrexone And Bupropion NB3244.53%18.49%n/rn/r
Naltrexone And Bupropion Placebo18.87%5.66%n/rn/r
Naltrexone And Bupropion BWL + NB medicationn/rn/rn/rn/r
Naltrexone And Bupropion BWL + Placebon/rn/rn/rn/r
Naltrexone And Bupropion Behavioral Weight Loss (BWL) + Naltrexone and Bupropion (NB) medicationn/rn/rn/rn/r
Naltrexone And Bupropion BWL + Placebon/rn/rn/rn/r
Naltrexone And Bupropion NB medicationn/rn/rn/rn/r
Naltrexone And Bupropion Placebon/rn/rn/rn/r
Naltrexone And Bupropion Naltrexone+Bupropion Medicationn/rn/rn/rn/r
Naltrexone And Bupropion Placebon/rn/rn/rn/r
Naltrexone And Bupropion Naltrexone/Bupropionn/rn/rn/rn/r
Naltrexone And Bupropion Placebon/rn/rn/rn/r
Orlistat Intensive Lifestyle Mod. Interventionn/rn/rn/rn/r
Orlistat Standard Lifestyle Interventionn/rn/rn/rn/r
Orlistat Placebon/rn/rn/rn/r
Orlistat Orlistatn/rn/rn/rn/r
Phentermine And Topiramate VI-0521 Low44.9%n/rn/rn/r
Phentermine And Topiramate VI-0521 Top66.7%n/rn/rn/r
Phentermine And Topiramate Placebo17.3%n/rn/rn/r
Phentermine And Topiramate VI-0521 Top66%n/rn/rn/r
Phentermine And Topiramate VI-0521 Mid62.1%n/rn/rn/r
Phentermine And Topiramate TPM 4639.2%n/rn/rn/r
Phentermine And Topiramate TPM 9248.6%n/rn/rn/r
Phentermine And Topiramate PHEN 7.543.3%n/rn/rn/r
Phentermine And Topiramate PHEN 1546.2%n/rn/rn/r
Phentermine And Topiramate Placebo15.5%n/rn/rn/r
Phentermine And Topiramate LSMT 12n/rn/rn/rn/r
Phentermine And Topiramate LSMT 24n/rn/rn/rn/r
Phentermine And Topiramate Phentermine & Topiramaten/rn/rn/rn/r
Phentermine And Topiramate Placebo Drugsn/rn/rn/rn/r
Phentermine And Topiramate Semaglutiden/rn/rn/rn/r
Phentermine And Topiramate Other anti-obesity medicationn/rn/rn/rn/r
Setmelanotide Setmelanotiden/rn/rn/rn/r
Setmelanotide Placebon/r0.05%n/rn/r
Setmelanotide Setmelanotiden/r55.6%n/rn/r
Setmelanotide Setmelanotide (Double-Blind)n/rn/rn/rn/r
Setmelanotide Placebo (Double-Blind)n/rn/rn/rn/r
Setmelanotide Setmelanotide (Open-label)n/rn/rn/rn/r
Setmelanotide Pivotal Cohortn/r32.3%n/rn/r
Setmelanotide 2 mgn/rn/rn/rn/r
Setmelanotide 2.5 mgn/rn/rn/rn/r
Setmelanotide 3 mgn/rn/rn/rn/r
Setmelanotide 20 mgn/rn/rn/rn/r
Setmelanotide 25 mgn/rn/rn/rn/r
Setmelanotide 3 mgn/rn/rn/rn/r
Setmelanotide 30 mgn/rn/rn/rn/r
Setmelanotide 20 mgn/rn/rn/rn/r
Setmelanotide 25 mgn/rn/rn/rn/r
Setmelanotide 30 mgn/rn/rn/rn/r
Setmelanotide Setmelanotiden/r45.5%n/rn/r
Setmelanotide Setmelanotiden/r80%n/rn/r
Setmelanotide Setmelanotide: PPL Groupn/rn/rn/rn/r
Setmelanotide Setmelanotide: BBS Groupn/rn/rn/rn/r
Setmelanotide 16p11.2 Cohortn/rn/rn/rn/r
Setmelanotide AS Cohortn/rn/rn/rn/r
Setmelanotide BBS Cohortn/rn/rn/rn/r
Setmelanotide MC4R Cohortn/rn/rn/rn/r
Setmelanotide POMC/PCSK1/LEPR Heterozygous Cohortn/rn/rn/rn/r
Setmelanotide POMC/PCSK1/LEPR Composite Heterozygous Cohortn/rn/rn/rn/r
Setmelanotide POMC/PCSK1/LEPR Compound Heterozygous Cohortn/rn/rn/rn/r
Setmelanotide SH2B1 Cohortn/rn/rn/rn/r
Setmelanotide SMS Cohortn/rn/rn/rn/r
Setmelanotide SRC1 Cohortn/rn/rn/rn/r
Setmelanotide Stage 1: Setmelanotide (Open-Label)n/rn/rn/rn/r
Setmelanotide Stage 2: Setmelanotide (Double-Blind)n/rn/rn/rn/r
Setmelanotide Stage 2: Placebo (Double-Blind)n/rn/rn/rn/r
Setmelanotide Placebon/rn/rn/rn/r
Setmelanotide Setmelanotide9.1%n/rn/rn/r
Setmelanotide Placebo5.6%n/rn/rn/r
Setmelanotide 0.5 mgn/rn/rn/rn/r
Setmelanotide 1.5 mgn/rn/rn/rn/r
Setmelanotide 2.5 mgn/rn/rn/rn/r
Setmelanotide Placebon/rn/rn/rn/r
Sibutramine Sibutraminen/rn/rn/rn/r
Sibutramine Placebon/rn/rn/rn/r
Tesofensine placebo armn/rn/rn/rn/r

Not shown

  • Semaglutide 2.4 mg: endpoint not reported
  • Semaglutide Semaglutide: endpoint not reported
  • Semaglutide Placebo (semaglutide): endpoint not reported
  • Semaglutide 1.0 mg: endpoint not reported
  • Semaglutide 2.4 mg: endpoint not reported
  • Semaglutide Semaglutide placebo I/II: endpoint not reported
  • Semaglutide Semaglutide: endpoint not reported
  • Semaglutide Placebo: endpoint not reported
  • Semaglutide 2.4 mg: endpoint not reported
  • Semaglutide Placebo, in trial: endpoint not reported
  • Semaglutide 2.4 mg: endpoint not reported
  • Semaglutide Semaglutide placebo OW: endpoint not reported
  • Semaglutide Semaglutide: endpoint not reported
  • Semaglutide Semaglutide placebo: endpoint not reported
  • Semaglutide 2.4 mg: endpoint not reported
  • Semaglutide Placebo, in trial: endpoint not reported
  • Semaglutide Insuline glargine U100 (reduced) + semaglutide: endpoint not reported
  • Semaglutide Insuline glargine U100 (titrated): endpoint not reported
  • Semaglutide 7.2 mg: endpoint not reported
  • Semaglutide 2.4 mg: endpoint not reported
  • Semaglutide Placebo: endpoint not reported
  • Semaglutide 2.4 mg: endpoint not reported
  • Semaglutide 2.4 mg: endpoint not reported
  • Semaglutide 1.7 mg: endpoint not reported
  • Semaglutide 1.7 mg: endpoint not reported
  • Semaglutide Semaglutide: endpoint not reported
  • Semaglutide Placebo (semaglutide): endpoint not reported
  • Semaglutide Semaglutide: endpoint not reported
  • Semaglutide Placebo: endpoint not reported
  • Semaglutide 2.4 mg: endpoint not reported
  • Semaglutide Placebo, in trial: endpoint not reported
  • Semaglutide Placebo: endpoint not reported
  • Semaglutide 2.4 mg: endpoint not reported
  • Semaglutide Semaglutide: endpoint not reported
  • Semaglutide Placebo (semaglutide): endpoint not reported
  • Tirzepatide 5 mg: endpoint not reported
  • Tirzepatide 10 mg: endpoint not reported
  • Tirzepatide Tirzepatide (lead-in): endpoint not reported
  • Tirzepatide Tirzepatide: endpoint not reported
  • Tirzepatide Placebo: endpoint not reported
  • Tirzepatide Tirzepatide MTD_GPI1: endpoint not reported
  • Tirzepatide Placebo_GPI1: endpoint not reported
  • Tirzepatide Tirzepatide MTD_GPI2: endpoint not reported
  • Tirzepatide Placebo_GPI2: endpoint not reported
  • Cagrilintide/semaglutide cagrilintide 2.4 mg and semaglutide 2.4 mg: endpoint not reported
  • Cagrilintide/semaglutide Placebo s.c.: endpoint not reported
  • Retatrutide 4 mg: endpoint not reported
  • Retatrutide 9 mg: endpoint not reported
  • Retatrutide 12 mg: endpoint not reported
  • Retatrutide Placebo: endpoint not reported
  • Survodutide 3.6 mg: endpoint not reported
  • Survodutide 6.0 mg: endpoint not reported
  • Survodutide Placebo: endpoint not reported
  • VK2735 2.5 mg: endpoint not reported
  • VK2735 15 mg: endpoint not reported
  • VK2735 Placebo 13 weeks: endpoint not reported
  • Eloralintide Placebo: endpoint not reported
  • Eloralintide 1 mg: endpoint not reported
  • Eloralintide 3 mg: endpoint not reported
  • Eloralintide 6 mg: endpoint not reported
  • Eloralintide 9 mg: endpoint not reported
  • Berobenatide Placebo: endpoint not reported
  • Dulaglutide Dulaglutide Arm: endpoint not reported
  • Dulaglutide Placebo Arm: endpoint not reported
  • Exenatide Group A: endpoint not reported
  • Exenatide Group B: endpoint not reported
  • Exenatide Exenatide: endpoint not reported
  • Exenatide Placebo: endpoint not reported
  • Exenatide Exenatide once weekly (EQW ): endpoint not reported
  • Exenatide Dapagliflozin (DAPA): endpoint not reported
  • Exenatide EQW plus DAPA: endpoint not reported
  • Exenatide Dapagliflozin plus Glucophage (MET ER): endpoint not reported
  • Exenatide Phentermine /Topiramate (PHEN/ TPM) ER: endpoint not reported
  • Exenatide Exenatide once weekly extended-release: endpoint not reported
  • Exenatide Matching placebo: endpoint not reported
  • Liraglutide 3.0mg: endpoint not reported
  • Liraglutide 3.0mg: endpoint not reported
  • Liraglutide Liraglutide Placebo, no Pre-diabetes: endpoint not reported
  • Liraglutide 3.0 mg: endpoint not reported
  • Liraglutide Placebo: endpoint not reported
  • Liraglutide Semaglutide: endpoint not reported
  • Liraglutide Liraglutide: endpoint not reported
  • Liraglutide Placebo (liraglutide): endpoint not reported
  • Liraglutide Liraglutide: endpoint not reported
  • Liraglutide Placebo: endpoint not reported
  • Liraglutide Liraglutide: endpoint not reported
  • Liraglutide Placebo: endpoint not reported
  • Liraglutide Metformin XR plus liraglutide: endpoint not reported
  • Liraglutide Metformin XR plus placebo: endpoint not reported
  • Liraglutide Liraglutide Pen Injector (Saxenda): endpoint not reported
  • Liraglutide Placebo liraglutide pen injector: endpoint not reported
  • Liraglutide Liraglutide: endpoint not reported
  • Liraglutide Placebo: endpoint not reported
  • Liraglutide Liraglutide + Metformin: endpoint not reported
  • Liraglutide 3.0 mg: endpoint not reported
  • Liraglutide 3.0 mg: endpoint not reported
  • Liraglutide 3.0 mg: endpoint not reported
  • Liraglutide 3.0 mg: endpoint not reported
  • Liraglutide 3.0 mg: endpoint not reported
  • Liraglutide Orlistat: endpoint not reported
  • Mazdutide 3/6 Milligrams (mg) Mazdutide: endpoint not reported
  • Mazdutide 10 mg: endpoint not reported
  • Mazdutide 16 mg: endpoint not reported
  • Mazdutide Placebo: endpoint not reported
  • Mazdutide 6 mg: endpoint not reported
  • Oral Semaglutide Oral semaglutide: endpoint not reported
  • Oral Semaglutide Oral semaglutide placebo: endpoint not reported
  • Oral Semaglutide 25 mg: endpoint not reported
  • Oral Semaglutide Oral semaglutide placebo: endpoint not reported
  • Oral Semaglutide 50 mg: endpoint not reported
  • Oral Semaglutide oral semaglutide placebo once daily: endpoint not reported
  • TERN-601 250 mg: endpoint not reported
  • TERN-601 500 mg: endpoint not reported
  • TERN-601 750 mg: endpoint not reported
  • TERN-601 Matching Placebo: endpoint not reported
  • HM15211 HM15211: endpoint not reported
  • HM15211 Placebo: endpoint not reported
  • Pramlintide Placebo-P + Placebo-M: endpoint not reported
  • Pramlintide 360 mcg: endpoint not reported
  • Pramlintide 5.0 mg: endpoint not reported
  • Pramlintide 2.5 mg: endpoint not reported
  • Pramlintide 5.0 mg: endpoint not reported
  • Pramlintide 1.25 mg: endpoint not reported
  • Pramlintide 2.5 mg: endpoint not reported
  • Pramlintide 5.0 mg: endpoint not reported
  • Pramlintide 1: endpoint not reported
  • Pramlintide 2: endpoint not reported
  • Pramlintide 3: endpoint not reported
  • Pramlintide Placebo: endpoint not reported
  • Pramlintide Pramlintide + Metreleptin: endpoint not reported
  • Pramlintide Pramlintide Acetate and Placebo: endpoint not reported
  • Pramlintide Lead-In Period: endpoint not reported
  • Naltrexone And Bupropion BWL + NB medication: endpoint not reported
  • Naltrexone And Bupropion BWL + Placebo: endpoint not reported
  • Naltrexone And Bupropion Behavioral Weight Loss (BWL) + Naltrexone and Bupropion (NB) medication: endpoint not reported
  • Naltrexone And Bupropion BWL + Placebo: endpoint not reported
  • Naltrexone And Bupropion NB medication: endpoint not reported
  • Naltrexone And Bupropion Placebo: endpoint not reported
  • Naltrexone And Bupropion Naltrexone+Bupropion Medication: endpoint not reported
  • Naltrexone And Bupropion Placebo: endpoint not reported
  • Naltrexone And Bupropion Naltrexone/Bupropion: endpoint not reported
  • Naltrexone And Bupropion Placebo: endpoint not reported
  • Orlistat Intensive Lifestyle Mod. Intervention: endpoint not reported
  • Orlistat Standard Lifestyle Intervention: endpoint not reported
  • Orlistat Placebo: endpoint not reported
  • Orlistat Orlistat: endpoint not reported
  • Phentermine And Topiramate LSMT 12: endpoint not reported
  • Phentermine And Topiramate LSMT 24: endpoint not reported
  • Phentermine And Topiramate Phentermine & Topiramate: endpoint not reported
  • Phentermine And Topiramate Placebo Drugs: endpoint not reported
  • Phentermine And Topiramate Semaglutide: endpoint not reported
  • Phentermine And Topiramate Other anti-obesity medication: endpoint not reported
  • Setmelanotide Setmelanotide: endpoint not reported
  • Setmelanotide Setmelanotide (Double-Blind): endpoint not reported
  • Setmelanotide Placebo (Double-Blind): endpoint not reported
  • Setmelanotide Setmelanotide (Open-label): endpoint not reported
  • Setmelanotide 2 mg: endpoint not reported
  • Setmelanotide 2.5 mg: endpoint not reported
  • Setmelanotide 3 mg: endpoint not reported
  • Setmelanotide 20 mg: endpoint not reported
  • Setmelanotide 25 mg: endpoint not reported
  • Setmelanotide 3 mg: endpoint not reported
  • Setmelanotide 30 mg: endpoint not reported
  • Setmelanotide 20 mg: endpoint not reported
  • Setmelanotide 25 mg: endpoint not reported
  • Setmelanotide 30 mg: endpoint not reported
  • Setmelanotide Setmelanotide: PPL Group: endpoint not reported
  • Setmelanotide Setmelanotide: BBS Group: endpoint not reported
  • Setmelanotide 16p11.2 Cohort: endpoint not reported
  • Setmelanotide AS Cohort: endpoint not reported
  • Setmelanotide BBS Cohort: endpoint not reported
  • Setmelanotide MC4R Cohort: endpoint not reported
  • Setmelanotide POMC/PCSK1/LEPR Heterozygous Cohort: endpoint not reported
  • Setmelanotide POMC/PCSK1/LEPR Composite Heterozygous Cohort: endpoint not reported
  • Setmelanotide POMC/PCSK1/LEPR Compound Heterozygous Cohort: endpoint not reported
  • Setmelanotide SH2B1 Cohort: endpoint not reported
  • Setmelanotide SMS Cohort: endpoint not reported
  • Setmelanotide SRC1 Cohort: endpoint not reported
  • Setmelanotide Stage 1: Setmelanotide (Open-Label): endpoint not reported
  • Setmelanotide Stage 2: Setmelanotide (Double-Blind): endpoint not reported
  • Setmelanotide Stage 2: Placebo (Double-Blind): endpoint not reported
  • Setmelanotide Placebo: endpoint not reported
  • Setmelanotide 0.5 mg: endpoint not reported
  • Setmelanotide 1.5 mg: endpoint not reported
  • Setmelanotide 2.5 mg: endpoint not reported
  • Setmelanotide Placebo: endpoint not reported
  • Sibutramine Sibutramine: endpoint not reported
  • Sibutramine Placebo: endpoint not reported
  • Tesofensine placebo arm: endpoint not reported

A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.